PACE Launches £6m Funding Round to Fight Deadly Bacterial Infections
PACE, a leading UK public-private collaboration targeting antimicrobial research, has launched its third £6m funding round. This initiative aims to combat the growing global crisis of antimicrobial resistance (AMR). The programme prioritises projects focusing on life-threatening bacterial infections and seeks innovative therapies targeting novel mechanisms of action.
Bacterial infections are becoming increasingly difficult to treat due to accelerating global entry of resistant bacteria worldwide. If left unchecked, these infections could cause more than eight million deaths annually by 2050 and cost the global economy an estimated $100 trillion. To address this urgent issue, PACE offers wraparound support to successful applicants, including expert guidance, strategic planning, and access to sector networks and resources.
The third funding round will provide up to £6m in support for up to eight projects addressing bacterial infections with the highest global entry burden. Each successful applicant will receive up to £1m over a two-year period. PACE is one of the UK's largest public-private collaborations targeting antimicrobial research, backed by a wider £30m investment.
AMR innovators worldwide are encouraged to apply for the third funding round, with the deadline for applications being June 30, 2023. PACE's commitment to funding novel approaches highlights the urgent need to tackle the growing global AMR crisis and overcome the limitations of existing antibacterial drugs.
